Risk of systemic adverse events after botulinum neurotoxin A treatment in cerebral palsy

Dev Med Child Neurol. 2018 Nov;60(11):1074. doi: 10.1111/dmcn.14025. Epub 2018 Aug 31.
No abstract available

Publication types

  • Comment

MeSH terms

  • Botulinum Toxins
  • Botulinum Toxins, Type A*
  • Cerebral Palsy*
  • Humans
  • Muscle Spasticity
  • Neuromuscular Agents
  • Risk

Substances

  • Neuromuscular Agents
  • Botulinum Toxins
  • Botulinum Toxins, Type A